Tuparstobart

图帕苏拜单抗

Report date: 2024/08/02 20:01:06

Base Information

Drug NameTuparstobart
Drug Alias NameINCAGN-02385INCAGN-2385
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitors
TargetsLymphocyte activation gene 3 protein
Therapy Area/IndicationsHead and Neck NeoplasmsMelanomaLymphoma, Follicular +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAgenus IncIncyte Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIncyte CorpIncyte Biosciences International SàrlUniversity Of Alabama At Birmingham
Active IndicationsN/A
Inactive IndicationsHead and Neck NeoplasmsMelanomaLymphoma, Follicular +[6] 

Other Information

ATC CodeN/A
Related LinksN/A